HDAC6 and brain cancer: The present study introduced molecular-, structural-based design and identification of new class of benzimidazole-based hydroxamic acid that involves a lead inhibitor with HDAC6 preferential inhibiting activity (HDAC6 IC50  = 510 nM) and on-target cytotoxic mechanism of action against CCHE-45 children brain cancer cells at (CCHE-45 IC50  = 112.76 μM).